| 15.845 1.53 (10.69%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.1  |
1-year : | 21.14 |
| Resists | First : | 15.5 |
Second : | 18.1 |
| Pivot price | 11.34 |
|||
| Supports | First : | 11.07 |
Second : | 8.34 |
| MAs | MA(5) : | 14.21 |
MA(20) : | 11.03 |
| MA(100) : | 11.99 |
MA(250) : | 11.76  |
|
| MACD | MACD : | 0.9 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 98.5 |
D(3) : | 96.8 |
| RSI | RSI(14): 76 |
|||
| 52-week | High : | 38.42 | Low : | 5.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ KRRO ] has closed below upper band by 7.2%. Bollinger Bands are 132.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 14.4 - 14.44 | 14.44 - 14.49 |
| Low: | 13.29 - 13.34 | 13.34 - 13.39 |
| Close: | 14.22 - 14.3 | 14.3 - 14.39 |
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Sat, 31 Oct 2026
Korro Bio, Inc. (KRRO) Seasonal returns chart - Yahoo Finance UK
Fri, 30 Oct 2026
Korro Bio, Inc. (KRRO) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Tue, 27 Oct 2026
BlackRock units amend their Korro Bio (KRRO) stake disclosure, excluding other business units. - Stock Titan
Mon, 26 Oct 2026
Korro Bio: 10% owner Lynx1 Capital Management LP buys $884,751 stock - Investing.com
Fri, 23 Oct 2026
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains? - Yahoo Finance
Thu, 22 Oct 2026
Korro Bio reports preclinical data for AATD treatment KRRO-111 - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 1.058e+007 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 1,480 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.433e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 228.3 % |
| Return on Equity (ttm) | -28 % |
| Qtrly Rev. Growth | 2.38e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -41.4 |
| EBITDA (p.s.) | -1.73814e+007 |
| Qtrly Earnings Growth | -9.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -68 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.38 |
| Price to Cash Flow | 5.17 |
| Dividend | 0 |
| Forward Dividend | 1.68e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|